Department of Pharmacy, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
The First Clinical Medical College of Anhui Medical University, Hefei, China.
Front Immunol. 2022 Feb 17;13:826337. doi: 10.3389/fimmu.2022.826337. eCollection 2022.
To unravel the oncogenic role of CDCA4 in different cancers from the perspective of tumor immunity.
Raw data on CDCA4 expression in tumor samples and paracancerous samples were obtained from TCGA and GTEX databases. In addition, we investigated pathological stages and the survival analysis of CDCA4 in pan-cancer across Gene Expression Profiling Interactive Analysis (GEPIA) database. Cox Proportional Hazards Model shows that high CDCA4 levels are associated with several vital indicators in oncology. On the one hand, we explored the correlation between CADA4 expression and tumor immune infiltration by the TIMER tool; On the other hand, we utilized the methods of CIBERSORT and ESTIMATE computational to evaluate the proportion of tumor infiltrating immune cells (TIIC) and the amounts of stromal and immune components based on TCGA database. The use of antineoplastic drugs and the expression of CDCA4 also showed a high correlation linear regression. Protein-Protein Interaction analysis was performed in the GeneMANIA database, and enrichment analysis was performed and predicted signaling pathways were identified by using Gene Ontology and Kyoto Encyclopedia of Genes. The correlation between CDCA4 expression with Copy number variations (CNV) and methylation is detailed, respectively. Molecular biology experiments including Western blotting, flow cytometry, EDU staining, Transwell and Wound Healing assay to validate the cancer promoting role of CDCA4 in hepatocellular carcinoma (HCC).
Most tumors highly expressed CDCA4. Elevated CDCA4 expression was associated with poor OS and DFS. There was a significant correlation between CDCA4 expression and TITCs. Moreover, markers of TIICs exhibited distinct patterns of CDCA4 associated immune infiltration. In addition, we pay attention to the association between the expression of CDCA4 and the use of the anti-tumor drugs. CDCA4 is related to biological progress (BP), cellular component (CC) and molecular function (MF). Dopaminergic Synapse, AMPK, Sphingolipid, Chagas Disease, mRNA Surveillance were significantly enriched pathways in positive and negative correlation genes with CDCA4. CNV is thought to be a positive correlation with CDCA4 expression. Conversely, methylation is negative correlation with CDCA4 expression. Molecular biology experiments confirm a cancer promoting role for CDCA4 in HCC.
CDCA4 may serve as a biomarker for cancer immunologic infiltration and poor prognosis, providing a new way of thinking for cancer treatment.
从肿瘤免疫的角度揭示 CDCA4 在不同癌症中的致癌作用。
从 TCGA 和 GTEX 数据库中获取 CDCA4 在肿瘤样本和癌旁样本中的表达原始数据。此外,我们还通过基因表达谱交互式分析 (GEPIA) 数据库研究了 CDCA4 在泛癌中的病理分期和生存分析。Cox 比例风险模型表明,CDCA4 水平高与肿瘤学中的几个重要指标相关。一方面,我们通过 TIMER 工具探索了 CDCA4 表达与肿瘤免疫浸润的相关性;另一方面,我们利用 CIBERSORT 和 ESTIMATE 计算方法,根据 TCGA 数据库评估肿瘤浸润免疫细胞 (TIIC) 的比例和基质及免疫成分的数量。抗肿瘤药物的使用和 CDCA4 的表达也显示出高度的相关性(线性回归)。在 GeneMANIA 数据库中进行蛋白质-蛋白质相互作用分析,并通过基因本体论和京都基因与基因组百科全书进行富集分析,预测信号通路。分别详细描述了 CDCA4 表达与拷贝数变异 (CNV) 和甲基化的相关性。包括 Western blot、流式细胞术、EDU 染色、Transwell 和伤口愈合实验在内的分子生物学实验,以验证 CDCA4 在肝细胞癌 (HCC) 中的促癌作用。
大多数肿瘤高度表达 CDCA4。CDCA4 表达升高与 OS 和 DFS 不良相关。CDCA4 表达与 TIIC 之间存在显著相关性。此外,TIIC 标志物表现出与 CDCA4 相关免疫浸润的不同模式。此外,我们还关注了 CDCA4 表达与抗肿瘤药物使用之间的关联。CDCA4 与生物学过程 (BP)、细胞成分 (CC) 和分子功能 (MF) 有关。多巴胺能突触、AMPK、鞘脂、恰加斯病、mRNA 监测在与 CDCA4 呈正相关和负相关的基因中显著富集。CNV 被认为与 CDCA4 表达呈正相关。相反,甲基化与 CDCA4 表达呈负相关。分子生物学实验证实了 CDCA4 在 HCC 中的促癌作用。
CDCA4 可作为肿瘤免疫浸润和预后不良的生物标志物,为癌症治疗提供新的思路。